retatrutide type 2 diabetes phase 2 trial In the 3 TRANSCEND-T2D-1 trial, patients with experienced: ✓ Up to 2% A1C reduction ✓ 90% achieved an A1C <7% ✓ 85% achieved an A1C <6.5% ✓ 46% Retatrutide Phase 2: Type 2

These are real advancements that will make effective GLP-1 treatment accessible to more people without the need for dubious supplements

Your gut isnt just about digestionits the foundation of your overall health.

Prioritize protein at every meal This is the single most impactful dietary change

That single target does a remarkable amount of work

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Patel D., Smith A

Patients seeking GLP-1 therapy should rely on FDA-approved medications with established efficacy profiles, including landmark trials like STEP (semaglutide) demonstrating approximately 15% body weight reduction and SCALE (liraglutide) showing 5-8% weight reduction, along with improved glycemic control in patients with diabetes